Galectin-3作为心脏生物标志物:实验室检测实施的关键要素
本文系统综述了Galectin-3作为心脏纤维化标志物在心力衰竭管理中的实验室检测实施要点,涵盖分析前标本采集与储存、传统免疫assay与新型生物传感器的分析性能、标准化问题(校准品溯源性、参考物质互换性、批间变异、室间质评、决策限建立)以及生物学混杂因素(肾功能、全身炎症、年龄)和临床工作流整合。文章强调标准化报告算法可提高机构间结果可比性,为Gal-3检测的标准化和临床适用性奠定基础。
要点
- Gal-3是心脏纤维化的有效标志物,可用于心衰管理,但临床使用需严格标准化分析前、分析和报告方法。
- 分析前因素包括标本类型(血清或血浆)、处理程序、储存稳定性和冻融效应,对结果可靠性至关重要。
- 标准化问题涉及校准品溯源性、参考物质互换性、批间变异、室间质评和基于证据的决策限建立。
核心结论
- Gal-3是有效且有前景的心脏纤维化标志物,可用于心力衰竭管理,但其临床应用需要严格标准化分析前、分析和报告方法。
- 通过整合检测工程、质量体系和基于证据的解释,本综合框架为标准化且临床相关的Gal-3检测奠定了基础。
研究设计与样本
- 本文为系统综述,检索范围未在摘要中明确报告。
主要发现
- 分析前考虑包括标本采集方案(血清或血浆)、处理程序、储存稳定性和冻融效应。
- 分析性能评估涵盖传统免疫assay(ELISA、CMIA、ECL)和新型生物传感器(电化学、等离子体),包括检测限、线性、精密度和交叉反应性等参数。
- 标准化问题围绕校准品溯源性、参考物质互换性、批间变异、参与外部质量评估和建立基于证据的决策限。
- 生物学混杂因素如肾脏和全身炎症以及年龄,基于心脏纤维化对循环水平没有影响。
- Gal-3可用于心力衰竭表型分型(HFpEF vs. HFrEF)、风险分层、与利钠肽和高敏肌钙蛋白联合应用以及抗纤维化治疗的监测。
关键数值与推荐
- 未报告具体数值标准或推荐条款。
临床怎么用
- 将Gal-3纳入临床工作流时需考虑生物学混杂因素如肾脏和全身炎症以及年龄。
- 使用标准化报告算法与实验室信息系统兼容以提高机构间结果可比性。
局限性
- 未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Galactoside-derived lectin galectin-3 (Gal-3) is an effective and promising cardiac fibrosis marker that can be used in heart failure management. Nevertheless, its clinical use demands strict standardization of preanalytical, analytical, and reporting methods. This systematic review addresses the key elements of implementation of Gal-3 testing in laboratory medicine. The preanalytical considerations will be specimen collection protocols (serum or plasma), handling procedures, storage stability, and freeze-thaw effects, which are critical in ensuring that the results are reliable. Analytical performance is the overall assessment of traditional immunoassays [enzyme-linked immunosorbent assay (ELISA), chemiluminescent magnetic microparticle immunoassay (CMIA), electrochemiluminescence (ECL)], and newer biosensors (electrochemical, plasmonic), including performance parameters such as limit of detection, linearity, precision, and cross-reactivity. The problems of standardization revolve around calibrator traceability, interchangeability of reference materials, lot-to-lot variance, involvement in external quality assessment, and establishment of decision limits based on evidence. The incorporation of Gal-3 into the clinical workflow must consider biological confounders such as renal and systemic inflammation and age, which have no effect on circulating levels based on cardiac fibrosis. Gal-3 plays a role in heart failure phenotyping [heart failure with preserved ejection fraction (HFpEF) vs. heart failure with reduced ejection fraction (HFrEF)], risk stratification, natriuretic peptides, high-sensitivity troponin, and monitoring of antifibrotic therapies. The inter-institutional comparability of results is improved by standardized reporting algorithms compatible with laboratory information systems. This comprehensive framework establishes a foundation for standardized and clinically pertinent Gal-3 testing by integrating assay engineering, quality systems, and evidence-based interpretation within diagnostic laboratory practice.
引用
- Bhat AA, Alghazwani Y, Chidambaram K, et al. Galectin-3 as a cardiac biomarker. Clin Chim Acta. 2025. PMID: 41360363. doi:10.1016/j.cca.2025.120777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。